Chronic liver disease, resulting from Hepatitis B virus (HBV), Hepatitis D virus (HDV), or Hepatitis
C virus (HCV) infections, contributes to a major health burden worldwide. The relatively high
cost of the HCV treatment brings concerns about the accessibility, especially in the developing
countries. Hence, there exists a need for cost effect interventions with high efficiency. The use
of DNA prime-viral vector has been validated in prime-boost vaccination. The use of Flavivirus
subgenomic replicons as DNA based vaccine will provide excellent stability and high expression
of the vaccine candidate genes in combination with immune activation…..